Mode
Text Size
Log in / Sign up

Intranasal ketamine shows similar pain relief to IV opioids for renal colic in ED meta-analysisIntranasal ketamine and IV opioids show similar pain relief for kidney stones

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider intranasal ketamine as an alternative to IV opioids for renal colic pain, but evidence remains limited.

This systematic review and meta-analysis pooled data from 4 randomized controlled trials involving 454 patients with renal colic in emergency department settings. The analysis compared intranasal ketamine (230 patients) against intravenous morphine or fentanyl (224 patients) for acute pain management. Primary outcomes were pain intensity measured using Visual Analog Scale or Numerical Rating Scale at multiple time points.

For pain scores at 5 minutes, the mean difference was -0.41 VAS/NRS (95% CI: -1.88 to 1.07, P = 0.59). At 15 minutes, the mean difference was -0.20 VAS/NRS (95% CI: -0.86 to 0.46, P = 0.56). At 30 minutes, the mean difference was 0.53 VAS/NRS (95% CI: -0.08 to 1.13, P = 0.09). None of these differences reached statistical significance. The need for rescue analgesia also showed no significant differences between groups.

Safety analysis revealed no significant differences in overall adverse events or specific events like nausea and dizziness between treatment groups. Serious adverse events and discontinuation rates were not reported. The analysis used random-effects models to pool data from the 4 included RCTs.

Key limitations include the small number of trials (only 4 RCTs) and the relatively small total sample size of 454 patients. Confidence intervals for pain scores were wide, encompassing both potential benefit and harm. Funding sources and conflicts of interest were not reported. For emergency clinicians managing renal colic, these findings suggest intranasal ketamine may offer similar short-term pain relief to intravenous opioids with comparable safety, but more robust evidence is needed before definitive conclusions can be drawn.

Researchers analyzed four clinical trials to compare two pain relief methods for patients with severe kidney stone pain in emergency departments. They looked at 454 patients total, with about half receiving pain medication through a nasal spray (intranasal ketamine) and the other half receiving it through an IV (intravenous morphine or fentanyl). The goal was to see if one method worked better or faster than the other.

The analysis measured pain levels at 5, 15, and 30 minutes after treatment. It found no significant difference in pain relief between the nasal spray and the IV medication at any of these times. There was also no difference in how often patients needed extra pain medication or in common side effects like nausea and dizziness.

The main reason to be careful with these results is that they come from only four studies involving 454 patients. The confidence intervals—a statistical measure of certainty—for the pain scores were wide, meaning the true effect could range from a small benefit to a small harm for either treatment. Readers should understand that this review does not prove the treatments are equal, but rather that current evidence from a small number of studies shows no clear difference in effectiveness or safety for this specific use in the emergency room.

What this means for you:
Early evidence shows intranasal ketamine may offer similar pain relief to IV opioids for kidney stones, but more research is needed.

Study Details

Study typeMeta analysis
Sample sizen = 454
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND AND IMPORTANCE: Renal colic pain is typically managed using intravenous opioids, but the intranasal route has emerged as a less invasive and time-efficient alternative. Intranasal ketamine has shown promise as a safe and effective analgesic for acute pain in emergency settings. OBJECTIVE: To compare the efficacy and safety of intranasal ketamine versus intravenous opioids for renal colic pain management in the emergency department. DESIGN, SETTINGS, AND PARTICIPANTS: PubMed, Embase, and Cochrane were systematically searched for randomized controlled trials (RCTs) comparing intranasal ketamine to intravenous morphine or intravenous fentanyl in patients with renal colic. INTERVENTION OR EXPOSURE: Intranasal ketamine as the primary intervention; comparators were intravenous morphine or fentanyl. OUTCOMES, MEASURE, AND ANALYSIS: The primary outcome was pain intensity at various time points, measured using the Visual Analog Scale (VAS) and Numerical Rating Scale (NRS). Secondary outcomes: need for rescue analgesia, incidence of adverse events, nausea, and dizziness. Data were pooled using random-effects models to calculate mean differences for continuous outcomes and risk ratios for binary outcomes, with 95% confidence intervals (CIs). All statistical analyses were performed using R Software, version 4.2.3. MAIN RESULTS: We included four RCTs, involving 454 patients, of whom 230 (50.6%) received intranasal ketamine. There were no significant differences between groups in pain scores at 5 min (mean difference: -0.41 VAS/NRS, 95% CI: -1.88 to 1.07, P  = 0.59), 15 min (mean difference: -0.20 VAS/NRS, 95% CI: -0.86 to 0.46, P  = 0.56), and 30 min (mean difference: 0.53 VAS/NRS, 95% CI: -0.08 to 1.13, P  = 0.09). No significant differences were found between groups in the need for rescue analgesia or in the incidence of adverse events, nausea, or dizziness. CONCLUSION: Intranasal ketamine demonstrated analgesic efficacy comparable to intravenous opioids at 5, 15, and 30 min, with no increase in adverse events or rescue analgesia requirements.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.